Stem Cell Transplantation

Our research and trials staff are dedicated and experienced professionals, interested in pushing the boundaries of our knowledge and testing new ideas in practical environments. Use the links below to jump to categorised trials.

CMV Impact
Type: Multi-centre, randomised, phase III  study
Eligibility: Patients planned for a T-deplete sibling allogeneic stem cell transplant where both the patient and donor are CMV sero-positive. Patient of age 18 or older and donor >16 years of age
Study details: Investigates the effect of adoptive cellular therapy in the management of CMV reactivation post-allograft Patients will be randomised to conventional anti-viral treatment as indicated with or without adoptive cellular therapy using either gamma catch selection or multimer selection methods.
RIC-UCBT
Type: Multicentre
Eligibility: Patients must be less than or equal to 60 and greater or equal to 2 years old. Patients with high risk, advanced or poorly responding haematological disease for which there is published evidence that reduced intensity (RIC) heamatopoietic stem cell transplantation is likely to be effective. Graft Cell Dose and Graft HLA Criteria:  – Selection of appropriate units for specific patients will be overseen by the cord blood unit selection committee  – Unit selection is based on cryopreserved total nucleated cell (TNC) dose and HLA-A,-B and -DRb1 match. HLA-A and -B must be matched at the antigen level and HLA-DRB1 at the allelic level. – All units must be >4/6 matched to the recipent. Double units must also be >4/6 matched to each other. This may include 0-2 antigen mismatches at the A or B or DRB1 loci. – If multiple units are available for a given degree od HLA match, the largest will be chosen.
Study details: Transplantation of Umbilical cord blood from unrelated donors in patients with heamatological disease using a reduced intensity conditioning redimen.
MAC-UCBT
Type: Multicentre
Eligibility: Subjects must me <45 years of age and greater or 28 days old. Patients with high risk, advanced or poorly responding haematological disease for which there is publisehd evidence that haematopoietic stem cell transplantation using myeloablative conditioning is likely to be effective. The individual patient’s disease status is such that there is no alternative therapy likely to achieve cure or provide a significant prolongation of disease-free survival.
Study details: Transplantation of Umbilical cord blood from unrelated donors in patients with haematological disease using a myeloablative conditioning redimen. To assess the safety and efficacy of unrelated donor umbilical cord blood transplantation (UCBT) using a myeloabloative preparative regimen, in multi-institution UK setting.
Immune-Reconstitution
Type: Multicentre
Eligibility: All patients – adult and childern who would receive an umbilical cord unit in the UK.  Disease criteria would be as those established for peripheral blood and bone marrow transplants as deemed appropriate by the group of transplant physicians at the respestive transplant centres.  All patients (or their patients- in case of minors) able to sign an informed consent.
Study details: To understand impact of speed and diversity of immune reconstitution on the outcome of unrelated cord blood transplantation.
Merck V212
Type: Multicentre, phase III, double-blind, ramdomized, placebo-controlled clinical trial.
Eligibility: Patient is 18 or older. Patient has prior history of varicella, antibodies to VZV (documented prior to receipt of blood products), or residence in a country with endemic VZV infection for 30 or more years or if patient is 30 years old, attended primary or secondary school in a country with endemic VZV infection. Patient is scheduled to undergous HCT for treatment of lymphoma or other indication, including any other malignancy or an indication that is not a malignancy within 60 days of enrollment.  Patient is highly unlikely to conceive during the time period starting 2 weeks prior to enrolment through 6 months from last vaccination dose.
Study details: To study the safety, tolerability, efficacy and immunogenicity of V212 in Recipients of Autologous Hematopoietic Cell transplants.  Vaccination with inactivated VZN vaccine will reduce the incidence of HZ compared with placebo among autologous HCT recipents.